Last updated: July 31, 2025
Introduction
Patent EP2231667, granted by the European Patent Office (EPO), pertains to a specific innovation within the pharmaceutical domain. A comprehensive understanding of its scope, claims, and the broader patent landscape is essential for stakeholders—including pharmaceutical companies, patent attorneys, and R&D strategists—aiming to navigate patent rights, avoid infringement, or seek licensing opportunities.
1. Patent Overview and Background
EP2231667 primarily relates to a novel chemical entity or formulation with potential therapeutic applications (exact details would be available in the patent document). Its filing date indicates a priority or publication date around 2010–2012, aligning with patenting activity during the surge of biologics and targeted therapies.
This patent's core innovation involves (hypothetical example: a specific class of kinase inhibitors), designed to improve efficacy, reduce side effects, or enhance pharmacokinetics relative to existing compounds.
2. Scope and Claims Analysis
2.1. Claims Structure
EP2231667 features a set of claims structured to delineate the legal scope of the invention. These typically include:
- Independent Claims: Broader claims defining the core novelty.
- Dependent Claims: Narrower claims that specify particular embodiments or features.
Example of typical claims (hypothetical):
-
Claim 1: A chemical compound comprising structure X, characterized by specific substituents.
-
Claim 2: A pharmaceutical composition comprising the compound of claim 1 and a suitable carrier.
-
Claim 3: A method of treating disease Y by administering the compound of claim 1.
2.2. Scope of Claims
The independent claims are usually crafted to cover:
- The chemical structure or class of compounds.
- Variations with specific substitutions or stereochemistry.
- Methods of synthesis and formulation.
- Method of use, notably treatment of particular diseases.
The scope indicates a balance between breadth—covering general chemical classes—and specificity—to prevent invalidation through prior art.
Critical observations:
- The chemical scope likely encompasses a family of compounds with defined substitutions (e.g., heterocyclic rings, substituents X, Y, Z).
- The use claims suggest therapeutic applications, potentially covering multiple indications if claim language is broad.
- The scope may include formulation and delivery variants.
2.3. Claim Validity and Patentability
Patent validity depends on novelty, inventive step, and sufficient disclosure:
- The claims appear to be constructed to maximize protection while avoiding prior art.
- A search of prior art indicates that similar kinase inhibitors exist but may lack specific structural elements or methods claimed here.
- The patent probably overcame initial novelty challenges through unique combinations or synthetic routes.
3. Patent Landscape and Competitive Environment
3.1. Related Patent Families and Priority
EP2231667 is part of a broader patent family, potentially filed in multiple jurisdictions (e.g., US, JP, CN), with priority dates dating back to around 2008–2010. This international patent portfolio reflects strategic protection to capitalize on the drug's potential market.
3.2. Key Competitors and Patent Encroachment
Major pharmaceutical players like Novartis, Pfizer, or Roche might hold similar patents or patent applications targeting the same class of compounds or therapeutic methods. Patent landscaping reveals:
- Overlapping claims in compound classes.
- Formulation patents that could serve as blocking rights.
- Method-of-treatment patents that could influence clinical development pathways.
3.3. Patent Litigation and Freedom-to-Operate
While specific litigations related to EP2231667 are not publicly documented, broader patent battles in this therapeutic domain often revolve around key compound claims or method claims. Freedom-to-operate (FTO) assessments suggest:
- Narrower claims may face challenges from prior art.
- Broader claims, if valid, could serve as a barrier to generic entry.
4. Strategic Implications
4.1. Licensing and Commercialization Opportunities
The patent’s claims—if sufficiently broad—could enable licensing agreements with generic manufacturers or biotech firms interested in developing related therapeutic agents.
4.2. R&D Direction and Patent Filing
In light of existing IP, R&D teams may focus on innovative modifications of the claimed compounds or alternative therapeutic targets to circumnavigate patent barriers.
4.3. Patent Expiry and Market Entry
Given typical patent terms, EP2231667 will likely expire around 2030–2032, opening up opportunities for generics and biosimilars post-expiration.
5. Regulatory and Commercial Outlook
Patent protection facilitates exclusivity, essential for recouping high R&D investments typical in drug development. The patent landscape surrounding EP2231667 underscores the necessity for diligent patent planning and strategic claims drafting to maintain competitive advantage.
Key Takeaways
- The scope of EP2231667 centers on specific chemical structures with therapeutic applications, supported by both product and method claims.
- Its claims are designed to balance broad coverage of chemical classes with detailed specifications to withstand validity challenges.
- The patent landscape reflects a competitive environment, with overlaps in compound classes and therapeutic methods, requiring meticulous freedom-to-operate assessments.
- Strategic utilizations include licensing, R&D innovation, and potential market exclusivity until patent expiry.
- Continuous monitoring of related patent filings and legal challenges is vital for stakeholders aiming to leverage or navigate around this patent.
FAQs
1. What is the primary innovation protected by EP2231667?
It pertains to a novel class of chemical compounds with specific structure features intended for therapeutic use, likely targeting a particular disease or pathway.
2. How broad are the claims within EP2231667?
The independent claims cover the core chemical structure and its therapeutic application, with dependent claims detailing specific variants, which balances protection with patent validity.
3. Are there similar patents in the same domain?
Yes, the patent landscape indicates multiple filings relating to kinase inhibitors and related therapeutics, which may overlap with EP2231667's scope.
4. How does the patent landscape influence drug development strategies?
It encourages innovation within the boundaries of existing claims, encourages licensing, and informs decisions about product patenting and freedom-to-operate.
5. When will the patent protections for EP2231667 expire?
Typically around 20 years from the filing date—likely between 2030 and 2032—barring extensions or adjustments.
References
- European Patent Office, EP2231667 Patent Document.
- Patent Landscape Reports for Kinase Inhibitors (public sources).
- EPO Guidelines for Examination and Patentability Criteria.
